Paolo Corradini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6791150/publications.pdf Version: 2024-02-01

		9264	14208
314	19,419	74	128
papers	citations	h-index	g-index
323	323	323	13899
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study. Clinical Infectious Diseases, 2023, 76, e426-e438.	5.8	23
2	Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome. Haematologica, 2022, 107, 1153-1162.	3.5	15
3	A prognostic model for patients with lymphoma and COVID-19: aÂmulticentre cohort study. Blood Advances, 2022, 6, 327-338.	5.2	28
4	Tâ€cell immune response after mRNA SARSâ€CoVâ€2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies. British Journal of Haematology, 2022, 196, 548-558.	2.5	73
5	COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Advances, 2022, 6, 2427-2433.	5.2	46
6	COVID-19 in vaccinated adult patients with hematological malignancies: preliminary results from EPICOVIDEHA. Blood, 2022, 139, 1588-1592.	1.4	70
7	Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Advances, 2022, 6, 920-930.	5.2	16
8	Managing hematological cancer patients during the COVID-19 pandemic: anÂESMO-EHA Interdisciplinary Expert Consensus. ESMO Open, 2022, 7, 100403.	4.5	32
9	Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma. International Journal of Molecular Sciences, 2022, 23, 3834.	4.1	0
10	Chemotherapy after <scp>PD</scp> â€l inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics. British Journal of Haematology, 2022, 198, 82-92.	2.5	12
11	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey. Blood Advances, 2022, 6, 3870-3874.	5.2	8
12	Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects <i>In Vivo</i> Expansion and Disease Response in Patients with Large B-cell Lymphoma. Clinical Cancer Research, 2022, 28, 3378-3386.	7.0	15
13	High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3120-3131.	1.6	29
14	A three-gene signature based on <i>MYC</i> , <i>BCL-2</i> and <i>NFKBIA</i> improves risk stratification in diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2405-2416.	3.5	8
15	Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT. Bone Marrow Transplantation, 2021, 56, 655-663.	2.4	7
16	Total body irradiation + fludarabine compared to busulfan + fludarabine as "reduced-toxicity conditioning―for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 481-491.	2.4	10
17	A brief rituximab, bendamustine, mitoxantrone (Râ€BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). British Journal of Haematology, 2021, 193, 280-289.	2.5	4
18	Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia, 2021, 35, 2672-2683	7.2	45

#	Article	IF	CITATIONS
19	Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score. Blood Cancer Journal, 2021, 11, 73.	6.2	7
20	Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis Lymphomas. Transplantation and Cellular Therapy, 2021, 27, 328.e1-328.e6.	1.2	2
21	Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood, 2021, 137, 3027-3036.	1.4	40
22	EPICOVIDEHA: A Ready to Use Platform for Epidemiological Studies in Hematological Patients With COVID-19. HemaSphere, 2021, 5, e612.	2.7	29
23	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. Bone Marrow Transplantation, 2021, 56, 2606-2609.	2.4	3
24	COVIDâ€19 elicits an impaired antibody response against SARSâ€CoVâ€2 in patients with haematological malignancies. British Journal of Haematology, 2021, 195, 371-377.	2.5	56
25	Functional Impact of Genomic Complexity on the Transcriptome of Multiple Myeloma. Clinical Cancer Research, 2021, 27, 6479-6490.	7.0	9
26	Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica, 2021, 106, 2578-2587.	3.5	15
27	<i>CDKN2A</i> deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Haematologica, 2021, 106, 2918-2926.	3.5	18
28	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology and Oncology, 2021, 14, 168.	17.0	189
29	Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial. Blood Cancer Journal, 2021, 11, 197.	6.2	5
30	Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs. Haematologica, 2020, 105, 193-200.	3.5	29
31	Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 509-518.	0.4	91
32	Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplantation, 2020, 55, 884-890.	2.4	13
33	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. British Journal of Haematology, 2020, 188, 907-917.	2.5	8
34	Selective inhibitors of nuclear export in aggressive B-cell lymphomas. Lancet Haematology,the, 2020, 7, e500-e501.	4.6	1
35	Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Lancet Haematology,the, 2020, 7, e861-e873.	4.6	34
36	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. BMC Cancer, 2020, 20, 1140.	2.6	12

#	Article	IF	CITATIONS
37	The neutrophil to lymphocyte ratio (NLR) and the presence of large nodal mass are independent predictors of early response: A subanalysis of the prospective phase II PETâ€2â€adapted HD0607 trial. Cancer Medicine, 2020, 9, 8735-8746.	2.8	10
38	Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e256-e262.	2.0	4
39	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematology,the, 2020, 7, e737-e745.	4.6	430
40	Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma. HemaSphere, 2020, 4, e402.	2.7	15
41	High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). Cancers, 2020, 12, 2242.	3.7	5
42	Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 2020, 13, 115.	17.0	32
43	Handling the COVID-19 pandemic in the oncological setting. Lancet Haematology,the, 2020, 7, e365-e366.	4.6	12
44	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplantation, 2020, 55, 2077-2086.	2.4	5
45	Early serum <scp>TARC</scp> reduction predicts prognosis in advancedâ€stage <scp>Hodgkin</scp> lymphoma patients treated with a <scp>PET</scp> â€adapted strategy. Hematological Oncology, 2020, 38, 501-508.	1.7	8
46	Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917.	12.8	99
47	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances, 2020, 4, 830-844.	5.2	54
48	Allogeneic Transplantation for Relapsed Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 365-380.	0.2	0
49	Revealing Transcriptome Deregulation upon Genomic Complexity in Multiple Myeloma. Blood, 2020, 136, 3-4.	1.4	0
50	Brentuximab Vedotin As Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T-Cell Lymphoma Patients: A Phase 2 Study of the Fondazione Italiana Linfomi. Blood, 2020, 136, 21-21.	1.4	1
51	Ocular disorders in multiple myeloma patients: cross-sectional study of prevalence and association with treatment. Leukemia and Lymphoma, 2019, 60, 477-482.	1.3	7
52	Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nature Communications, 2019, 10, 3835.	12.8	183
53	Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma. British Journal of Cancer, 2019, 121, 567-577.	6.4	6
54	INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL. Hematological Oncology, 2019, 37, 505-507.	1.7	2

#	Article	IF	CITATIONS
55	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica, 2019, 104, 2241-2248.	3.5	13
56	Integration of transcriptional and mutational data simplifies the stratification of peripheral T ell lymphoma. American Journal of Hematology, 2019, 94, 628-634.	4.1	16
57	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. JAMA Oncology, 2019, 5, 715.	7.1	44
58	Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Advances, 2019, 3, 1103-1117.	5.2	23
59	PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL. Blood Advances, 2019, 3, 360-369.	5.2	92
60	CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS. Hematological Oncology, 2019, 37, 308-310.	1.7	4
61	CAR Tâ€cells: Driving in the Fast Lane. HemaSphere, 2019, 3, e209.	2.7	1
62	Are We Ready to Treat Diffuse Large Bâ€cell and Highâ€Grade Lymphoma According to Major Genetic Subtypes?. HemaSphere, 2019, 3, e284.	2.7	9
63	First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer Journal, 2019, 9, 100.	6.2	33
64	Real-life feasibility of salvage allogeneic transplantation in peripheral T-cell lymphomas. Bone Marrow Transplantation, 2019, 54, 1237-1244.	2.4	5
65	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. Leukemia, 2019, 33, 1047-1051.	7.2	27
66	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. Cancer, 2019, 125, 90-98.	4.1	15
67	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. Digestive and Liver Disease, 2019, 51, 419-424.	0.9	9
68	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. Leukemia and Lymphoma, 2019, 60, 1204-1213.	1.3	4
69	Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival. Leukemia and Lymphoma, 2019, 60, 101-109.	1.3	7
70	Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party. British Journal of Haematology, 2018, 181, 86-96.	2.5	23
71	Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1357-1366.	2.5	8
72	Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplantation, 2018, 53, 255-263.	2.4	14

#	Article	IF	CITATIONS
73	Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia, 2018, 32, 979-985.	7.2	25
74	Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplantation, 2018, 53, 461-473.	2.4	28
75	CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide. Bone Marrow Transplantation, 2018, 53, 1522-1531.	2.4	22
76	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 406-409.	2.0	16
77	Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines. Leukemia, 2018, 32, 1043-1047.	7.2	87
78	Daratumumab plus bortezomib and dexamethasone <i>versus</i> bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica, 2018, 103, 2079-2087.	3.5	225
79	Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA. Journal of Molecular Diagnostics, 2018, 20, 859-870.	2.8	45
80	Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors. Annals of Hematology, 2018, 97, 1301-1315.	1.8	6
81	Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia, 2018, 32, 2604-2616.	7.2	137
82	T-Cell Lymphomas. , 2018, , 1343-1380.		1
83	Genomic patterns of progression in smoldering multiple myeloma. Nature Communications, 2018, 9, 3363.	12.8	163
84	Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 533-540.	0.4	9
85	Romidepsin-CHOEP Plus Intensification with up-Front Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: Final Results of Phase Ib PTCL13 Study of the Fondazione Italiana Linfomi. Blood, 2018, 132, 2902-2902.	1.4	3
86	Carfilzomib, bendamustine, and dexamethasone (KBd) in advanced multiple myeloma: The EMN09-trial Journal of Clinical Oncology, 2018, 36, 8019-8019.	1.6	8
87	Whole Genome Sequencing Reveals Recurrent Structural Driver Events in Peripheral T-Cell Lymphomas Not Otherwise Specified. Blood, 2018, 132, 4115-4115.	1.4	0
88	Bronchial fibroepithelial polyp: a clinicoâ€radiologic, bronchoscopic, histopathological and <i>inâ€situ</i> hybridisation study of 15 cases of a poorly recognised lesion. Clinical Respiratory Journal, 2017, 11, 43-48.	1.6	11
89	Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?. Expert Review of Hematology, 2017, 10, 479-492.	2.2	34
90	Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 1102-1109.	2.0	9

#	Article	IF	CITATIONS
91	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2017, 23, 1549-1554.	2.0	25
92	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert Opinion on Biological Therapy, 2017, 17, 821-836.	3.1	4
93	Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus lowâ€dose dexamethasone: A pooled analysis. European Journal of Haematology, 2017, 99, 199-206.	2.2	21
94	Nextâ€generation sequencing of a family with a high penetrance of monoclonal gammopathies for the identification of candidate risk alleles. Cancer, 2017, 123, 3701-3708.	4.1	12
95	Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2017, 52, 372-380.	2.4	53
96	Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research, 2017, 62, 91-97.	0.8	16
97	Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients. Bone Marrow Transplantation, 2017, 52, 1602-1608.	2.4	13
98	ALLOGENEIC TRANSPLANTATION IN HODGKIN'S LYMPHOMA AFTER A FAILED AUTOGRAFT: LONG TERM OUTCOMES AND GRAFT-VERSUS-HOST DISEASE FREE/RELAPSE-FREE SURVIVAL (GRFS). Hematological Oncology, 2017, 35, 169-190.	1.7	0
99	FIL-PTCL13: PHASE IB/II STUDY OF ROMIDEPSIN/CHOEP FOLLOWED BY HIGH-DOSE CHEMOTHERAPY AND TRANSPLANTATION IN UNTREATED PERIPHERAL T-CELL LYMPHOMAS Hematological Oncology, 2017, 35, 426-426.	1.7	Ο
100	Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica, 2017, 102, 1931-1935.	3.5	11
101	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. Haematologica, 2017, 102, e423-e426.	3.5	7
102	Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2017, 35, 3425-3432.	1.6	132
103	Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. Oncotarget, 2017, 8, 91703-91710.	1.8	21
104	THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, e2016045.	1.3	4
105	Critical concepts, practice recommendations, and research perspectives of pixantrone therapy in nonâ€Hodgkin lymphoma: a <scp>SIE</scp> , <scp> SIES</scp> , and <scp>GITMO</scp> consensus paper. European Journal of Haematology, 2016, 97, 554-561.	2.2	9
106	Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease. Transplantation, 2016, 100, e147-e155.	1.0	40
107	A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients. Journal of Hematology and Oncology, 2016, 9, 38.	17.0	34
108	Post-transplant cyclophosphamide-based haplo-identical transplantation as alternative to matched sibling or unrelated donor transplantation for non-Hodgkin lymphoma: a registry study by the European society for blood and marrow transplantation. Leukemia, 2016, 30, 2086-2089.	7.2	45

#	Article	IF	CITATIONS
109	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood, 2016, 128, 497-503.	1.4	144
110	Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2016, 34, 4015-4022.	1.6	66
111	High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression. Blood Cancer Journal, 2016, 6, e491-e491.	6.2	4
112	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Annals of Oncology, 2016, 27, 2251-2257.	1.2	40
113	Circulating miRNA panel for prediction of acute graft-versus-host disease inÂlymphoma patients undergoing matched unrelated hematopoietic stem cellÂtransplantation. Experimental Hematology, 2016, 44, 624-634.e1.	0.4	26
114	Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program. Leukemia and Lymphoma, 2016, 57, 2370-2374.	1.3	5
115	Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study. International Journal of Radiation Oncology Biology Physics, 2016, 94, 783-791.	0.8	35
116	Carfilzomib in Combination with Bendamustine and Dexamethasone (CBd) in Relapsed and/or Refractory Patients with Multiple Myeloma: The Phase I/II EMN09 Study. Blood, 2016, 128, 3334-3334.	1.4	5
117	Rituximab for indolent lymphomas before and after allogeneic hematopoietic stem cell transplantation. Current Opinion in Hematology, 2015, 22, 469-475.	2.5	0
118	Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects. Clinical Cancer Research, 2015, 21, 3740-3749.	7.0	110
119	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 507-513.	0.4	13
120	An uncommon cause of weaning failure from mechanical ventilation. Intensive Care Medicine, 2015, 41, 327-328.	8.2	0
121	Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. Bone Marrow Transplantation, 2015, 50, 505-510.	2.4	16
122	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1068-1073.	2.0	46
123	Brentuximab Vedotin in Patients With Hodgkin Lymphoma and a Failed Allogeneic Stem Cell Transplantation: Results From a Named Patient Program at Four Italian Centers. Oncologist, 2015, 20, 323-328.	3.7	29
124	Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 404-408.	0.4	18
125	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood, 2015, 125, 2855-2864.	1.4	132
126	Current status of haematopoietic autologous stem cell transplantation in lymphoid malignancies: a European perspective. European Journal of Haematology, 2015, 94, 12-22.	2.2	18

#	Article	IF	CITATIONS
127	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncology, The, 2015, 16, 1525-1536.	10.7	143
128	Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology, 2015, 33, 3459-3466.	1.6	138
129	Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2015, 26, v108-v115.	1.2	172
130	Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1617-1629.	10.7	289
131	Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents. Leukemia and Lymphoma, 2015, 56, 1969-1974.	1.3	3
132	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. Leukemia, 2015, 29, 464-473.	7.2	64
133	Phase II Study of the Fondazione Italiana Linfomi on Gemcitabine Plus Romidepsin (GEMRO Regimen) in Relapsed and Refractory Peripheral T-Cell Lymphoma Patients. Blood, 2015, 126, 3937-3937.	1.4	1
134	Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia and Lymphoma, 2014, 55, 331-336.	1.3	25
135	Plerixafor â€~on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF. Bone Marrow Transplantation, 2014, 49, 453-455.	2.4	8
136	Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomide. Leukemia and Lymphoma, 2014, 55, 2032-2037.	1.3	22
137	Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research, 2014, 20, 5641-5651.	7.0	31
138	Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. British Journal of Haematology, 2014, 166, 140-142.	2.5	31
139	SIE-SIES-GITMO Guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukaemias. Annals of Oncology, 2014, 25, 2339-2350.	1.2	15
140	Experts' considerations on <scp>HLA</scp> â€haploidentical stem cell transplantation. European Journal of Haematology, 2014, 93, 187-197.	2.2	24
141	Phase <scp>IA</scp> / <scp>II</scp> , multicentre, openâ€label study of the <scp>CD</scp> 40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced nonâ€ <scp>H</scp> odgkin or <scp>H</scp> odgkin lymphoma. British Journal of Haematology, 2014, 164, 258-265.	2.5	65
142	Graft Monocytic Myeloid-Derived Suppressor Cell Content Predicts the Risk of Acute Graft-versus-Host Disease after Allogeneic Transplantation of Granulocyte Colony-Stimulating Factor–Mobilized Peripheral Blood Stem Cells. Biology of Blood and Marrow Transplantation, 2014, 20, 2049-2055.	2.0	60
143	Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1982-1988.	2.0	14
144	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia, 2014, 28, 1885-1891.	7.2	83

#	Article	IF	CITATIONS
145	Autologous Transplantation and Maintenance Therapy in Multiple Myeloma. New England Journal of Medicine, 2014, 371, 895-905.	27.0	683
146	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncology, The, 2014, 15, 1195-1206.	10.7	695
147	Autologous Stem Cell Transplantation for T-Cell Lymphomas. Seminars in Hematology, 2014, 51, 59-66.	3.4	16
148	Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 885-890.	2.0	42
149	High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib. Haematologica, 2014, 99, e14-e16.	3.5	42
150	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?. Blood, 2014, 124, 3841-3849.	1.4	185
151	Molecular Methods for Detection of Minimal Residual Disease Following Transplantation in Lymphoid and Plasma Cell Disorders. Methods in Molecular Biology, 2014, 1109, 209-237.	0.9	3
152	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 581-588.	4.1	61
153	Current state of art for transplantation paradigms in peripheral T-cell lymphomas. Expert Review of Hematology, 2013, 6, 465-474.	2.2	3
154	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576.	1.2	193
155	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 424-428.	2.0	24
156	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. Biology of Blood and Marrow Transplantation, 2013, 19, 940-948.	2.0	20
157	A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. British Journal of Haematology, 2013, 160, 649-659.	2.5	111
158	Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. Haematologica, 2013, 98, 1232-1236.	3.5	65
159	Successful second autologous engraftment after long duration storage of hematopoietic stem cells. Bone Marrow Transplantation, 2013, 48, 1480-1481.	2.4	2
160	Longâ€ŧerm molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. European Journal of Haematology, 2013, 90, 340-344.	2.2	2
161	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. Leukemia, 2013, 27, 2086-2091.	7.2	37
162	Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood, 2013, 122, 2799-2806.	1.4	80

#	Article	IF	CITATIONS
163	Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood, 2013, 121, 5055-5063.	1.4	171
164	Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood, 2013, 122, 1376-1383.	1.4	74
165	Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood, 2013, 122, 4111-4118.	1.4	90
166	Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica, 2013, 98, 1014-1021.	3.5	98
167	High-Dose Rituximab In The Conditioning Regimen Before Allogeneic Stem Cell Transplantation Decreases Deaths Related To Gvhd Without Affecting The Anti-Lymphoma Effect. Blood, 2013, 122, 2059-2059.	1.4	2
168	Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas. , 2013, , 229-242.		0
169	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. Leukemia, 2012, 26, 1779-1785.	7.2	14
170	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia, 2012, 26, 520-526.	7.2	129
171	Challenges for the next decade: allogeneic stem cell transplantation in chronic lymphocytic leukemia. Leukemia Supplements, 2012, 1, S33-S34.	0.1	0
172	Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood, 2012, 119, 933-939.	1.4	260
173	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leukemia and Lymphoma, 2012, 53, 789-795.	1.3	13
174	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. Biology of Blood and Marrow Transplantation, 2012, 18, 617-626.	2.0	75
175	SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. Annals of Hematology, 2012, 91, 875-888.	1.8	28
176	Longâ€ŧerm patterns of humoral and cellular response after vaccination against influenza A (<scp>H</scp> 1 <scp>N</scp> 1) in patients with hematologic malignancies. European Journal of Haematology, 2012, 89, 111-119.	2.2	16
177	Phase <scp>II</scp> study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2012, 158, 108-119.	2.5	36
178	Responseâ€adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progressionâ€free survival in transplanted patients with multiple myeloma. American Journal of Hematology, 2012, 87, 150-154.	4.1	8
179	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1) Journal of Clinical Oncology, 2012, 30, e18572-e18572.	1.6	5
180	Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. Leukemia and Lymphoma, 2011, 52, 1262-1270.	1.3	11

#	Article	IF	CITATIONS
181	Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. European Journal of Cancer, 2011, 47, 814-818.	2.8	16
182	Allogeneic transplantation for Hodgkin's lymphoma. British Journal of Haematology, 2011, 152, 261-272.	2.5	22
183	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Annals of Oncology, 2011, 22, 1614-1621.	1.2	42
184	Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. Toxicology, 2011, 283, 18-23.	4.2	12
185	Tandem Autologous/Reduced-Intensity Conditioning Allogeneic Stem-Cell Transplantation Versus Autologous Transplantation in Myeloma: Long-Term Follow-Up. Journal of Clinical Oncology, 2011, 29, 3016-3022.	1.6	171
186	Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma. Journal of Clinical Oncology, 2011, 29, 814-824.	1.6	151
187	Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. Haematologica, 2011, 96, 937-942.	3.5	62
188	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. Blood, 2011, 118, 3976-3976.	1.4	12
189	Allogeneic transplantation for lymphoma: long-term outcome. Current Opinion in Hematology, 2010, 17, 522-530.	2.5	8
190	Pretransplantation [18â€F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive nonâ€Hodgkin lymphoma undergoing reducedâ€intensity conditioning followed by allogeneic stem cell transplantation. Cancer, 2010, 116, 5001-5011.	4.1	36
191	Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. Bone Marrow Transplantation, 2010, 45, 505-512.	2.4	14
192	Immune reconstitution inflammatory syndrome associated with <i>Aspergillus terreus</i> pulmonary infection in an autologous stem cell transplant recipient. Transplant Infectious Disease, 2010, 12, 64-68.	1.7	13
193	Bortezomib As Induction Before Autologous Transplantation, Followed by Lenalidomide As Consolidation-Maintenance in Untreated Multiple Myeloma Patients. Journal of Clinical Oncology, 2010, 28, 800-807.	1.6	166
194	High-Dose Therapy and Autologous Stem-Cell Transplantation in Waldenström Macroglobulinemia: The Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2010, 28, 2227-2232.	1.6	131
195	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood, 2010, 115, 3671-3677.	1.4	151
196	Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, The, 2010, 376, 2075-2085.	13.7	770
197	Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. European Journal of Haematology, 2009, 82, 93-105.	2.2	21
198	Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Experimental Hematology, 2009, 37, 791-798.	0.4	90

#	Article	IF	CITATIONS
199	The hematopoietic cell transplantation comorbidity index (HCT-Cl) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia, 2009, 23, 1131-1138.	7.2	111
200	Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. Bone Marrow Transplantation, 2009, 44, 237-242.	2.4	18
201	Advances in mobilization for the optimization of autologous stem cell transplantation. Leukemia and Lymphoma, 2009, 50, 1412-1421.	1.3	48
202	Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. Haematologica, 2009, 94, 654-662.	3.5	62
203	Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood, 2009, 113, 4771-4779.	1.4	69
204	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood, 2009, 113, 3375-3382.	1.4	92
205	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2009, 114, 5264-5270.	1.4	366
206	Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leukemia and Lymphoma, 2008, 49, 2156-2162.	1.3	143
207	Eosinophilic Globules in Bronchoalveolar Lavage Fluid of Patients With Systemic Sclerosis–Related Interstitial Lung Disease. American Journal of Clinical Pathology, 2008, 130, 927-933.	0.7	1
208	Rituximab Improves the Efficacy of High-Dose Chemotherapy With Autograft for High-Risk Follicular and Diffuse Large B-Cell Lymphoma: A Multicenter Gruppo Italiano Terapie Innnovative nei Linfomi Survey. Journal of Clinical Oncology, 2008, 26, 3166-3175.	1.6	68
209	Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients?. Nature Clinical Practice Oncology, 2008, 5, 254-255.	4.3	0
210	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood, 2008, 111, 4004-4013.	1.4	243
211	Traumatic Neuroma of the Bronchi: Bronchoscopy and Histology of a Hitherto Unreported Lesion. American Journal of Surgical Pathology, 2008, 32, 640-641.	3.7	9
212	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations Blood, 2008, 112, 2144-2144.	1.4	2
213	Phase II Trial of Combination of the Histone Deacetylase Inhibitor ITF2357 and Meclorethamine Demonstrates Clinical Activity and Safety in Heavily Pretreated Patients with Relapsed/Refractory Hodgkin Lymphoma (HL). Blood, 2008, 112, 2586-2586.	1.4	5
214	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2008, 112, 3303-3303.	1.4	26
215	RIC Allogeneic Transplantation Improves the Overall and Progression- Free Survival of Hodgkin Lymphoma Patients Relapsing after Autologous Transplantation: A GITMO Retrospective Study Based on Time of HLATyping and Donor Availability. Blood, 2008, 112, 460-460.	1.4	0
216	Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network. Journal of Clinical Oncology, 2007, 25, 4459-4465.	1.6	301

#	Article	IF	CITATIONS
217	Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leukemia and Lymphoma, 2007, 48, 759-766.	1.3	27
218	Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. Leukemia and Lymphoma, 2007, 48, 1496-1501.	1.3	14
219	IFN-γ Enhances the Antimyeloma Activity of the Fully Human Anti–Human Leukocyte Antigen-DR Monoclonal Antibody 1D09C3. Cancer Research, 2007, 67, 3269-3275.	0.9	18
220	Antitumor effects of HSV-TK–engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood, 2007, 109, 4698-4707.	1.4	171
221	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. Biology of Blood and Marrow Transplantation, 2007, 13, 497-499.	2.0	5
222	Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. Haematologica, 2007, 92, 418-420.	3.5	15
223	Current role of allogeneic stem cell transplantation in follicular lymphoma. Haematologica, 2007, 92, 580-582.	3.5	1
224	Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica, 2007, 92, 1513-1518.	3.5	34
225	Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia, 2007, 21, 12-17.	7.2	349
226	Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). Leukemia, 2007 21 1802-1811	7.2	66
227	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia, 2007, 21, 2316-2323.	7.2	142
228	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. European Journal of Haematology, 2007, 78, 330-337.	2.2	25
229	Molecular Methods Used for The Detection of Autologous Graft Contamination in Lymphoid Disorders. Methods in Molecular Medicine, 2007, 134, 179-196.	0.8	1
230	Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. Blood, 2006, 107, 3415-3416.	1.4	75
231	Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. Bone Marrow Transplantation, 2006, 37, 311-315.	2.4	2
232	Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. Bone Marrow Transplantation, 2006, 37, 1135-1141.	2.4	98
233	Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. Leukemia, 2006, 20, 329-335.	7.2	42
234	Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia, 2006, 20, 1533-1538.	7.2	235

#	Article	IF	CITATIONS
235	Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. Leukemia, 2006, 20, 1840-1847.	7.2	18
236	CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. Experimental Hematology, 2006, 34, 721-727.	0.4	25
237	Incidence of Secondary Myelodysplastic Syndrome/Acute Leukemia in 1,266 Lymphoma Patients Following High-Dose Therapy and Autograft: A Study from GITIL (Gruppo Italiano Terapie Innovative nei) Tj ETQq1	110478431	. 4 .rgBT /Ov€
238	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma Blood, 2006, 108, 3158-3158.	1.4	1
239	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Haematologica, 2006, 91, 837-9.	3.5	38
240	Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2005, 35, 121-124.	2.4	21
241	The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplantation, 2005, 35, 609-617.	2.4	59
242	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, 2005, 19, 1029-1033.	7.2	149
243	Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. Experimental Hematology, 2005, 33, 920-927.	0.4	40
244	Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer, 2005, 104, 2099-2103.	4.1	50
245	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. Journal of Clinical Oncology, 2005, 23, 5334-5346.	1.6	125
246	Effect of Age and Previous Autologous Transplantation on Nonrelapse Mortality and Survival in Patients Treated With Reduced-Intensity Conditioning and Allografting for Advanced Hematologic Malignancies. Journal of Clinical Oncology, 2005, 23, 6690-6698.	1.6	58
247	Role of stem cell transplantation in myeloma. Hematology, 2005, 10, 127-128.	1.5	2
248	Immune-mediated attack in relapsed Hodgkin's lymphoma. Lancet, The, 2005, 365, 1906-1908.	13.7	14
249	Molecular Modeling of Stereo- and Regioselectivity of Group 4 Heterocenes in the Polymerization of Propene. Macromolecules, 2005, 38, 3973-3976.	4.8	14
250	Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 2004, 22, 2172-2176.	1.6	301
251	Long-Term Follow-Up of Indolent Lymphoma Patients Treated With High-Dose Sequential Chemotherapy and Autografting: Evidence That Durable Molecular and Clinical Remission Frequently Can Be Attained Only in Follicular Subtypes. Journal of Clinical Oncology, 2004, 22, 1460-1468.	1.6	116
252	Do New Century Catalysts Unravel the Mechanism of Stereocontrol of Old Zieglerâ^'Natta Catalysts?. Accounts of Chemical Research, 2004, 37, 231-241.	15.6	232

#	Article	IF	CITATIONS
253	Do New Century Catalysts Unravel the Mechanism of Stereocontrol of Old Ziegler—Natta Catalysts?. ChemInform, 2004, 35, no.	0.0	0
254	Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. Blood, 2004, 103, 3287-3295.	1.4	47
255	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease Blood, 2004, 104, 808-808.	1.4	5
256	Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). Haematologica, 2004, 89, 717-41.	3.5	48
257	Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. Experimental Hematology, 2003, 31, 784-788.	0.4	13
258	High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplantation, 2003, 31, 767-773.	2.4	15
259	Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2003, 32, 791-793.	2.4	10
260	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia, 2003, 17, 841-848.	7.2	180
261	PCR-Detectable Nonneoplastic Bcl-2/IgH Rearrangements Are Common in Normal Subjects and Cancer Patients at Diagnosis but Rare in Subjects Treated With Chemotherapy. Journal of Clinical Oncology, 2003, 21, 1398-1403.	1.6	35
262	Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood, 2003, 102, 749-755.	1.4	193
263	Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood, 2003, 102, 1927-1929.	1.4	176
264	Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood, 2002, 99, 75-82.	1.4	147
265	Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood, 2002, 99, 4234-4236.	1.4	209
266	High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2002, 100, 1559-1565.	1.4	89
267	Cytomegalovirus infection in cancer patients receiving granulocyte transfusions. Blood, 2002, 99, 390-391.	1.4	10
268	Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. British Journal of Haematology, 2002, 117, 642-645.	2.5	11
269	Central Nervous System Relapse in a Patient with Mantle Cell Lymphoma in Continuous Clinical and Molecular Remission at Six Years Since Autografting. Leukemia and Lymphoma, 2001, 40, 679-682.	1.3	6
270	Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. Annals of Oncology, 2001, 12, 1693-1698.	1.2	55

#	Article	IF	CITATIONS
271	High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity. Leukemia, 2001, 15, 256-263.	7.2	28
272	Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma. Leukemia, 2001, 15, 1941-1949.	7.2	49
273	A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Experimental Hematology, 2001, 29, 183-193.	0.4	64
274	P1. Immunoablation with t cell depleted autologous peripheral blood stem cell rescue produces complete remission in thrombocytopenic purpura (TTP) recidivant and refractory to standard treatment. Annals of the Rheumatic Diseases, 2001, 60, 708-716.	0.9	0
275	What Do the People Think (and Know) About Informed Consent for Participation in a Medical Trial. Archives of Internal Medicine, 2001, 161, 768-769.	3.8	9
276	Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft. Bone Marrow Transplantation, 2000, 26, 1185-1191.	2.4	59
277	Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft. Leukemia, 2000, 14, 740-747.	7.2	35
278	Geometry and Stability of Titanium Chloride Species Adsorbed on the (100) and (110) Cuts of the MgCl2Support of the Heterogeneous Zieglerâ `Natta Catalysts. Macromolecules, 2000, 33, 8953-8962.	4.8	127
279	Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells. Journal of Clinical Oncology, 1999, 17, 208-208.	1.6	222
280	Hemopoietic Progenitor Cell Mobilization and Harvest Following an Intensive Chemotherapy Debulking in Indolent Lymphoma Patients. Stem Cells, 1999, 17, 55-61.	3.2	26
281	Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia, 1999, 13, 1456-1462.	7.2	37
282	Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies. Leukemia, 1999, 13, 1691-1695.	7.2	42
283	C-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs. Bone Marrow Transplantation, 1998, 21, 401-407.	2.4	55
284	Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplantation, 1998, 22, 449-455.	2.4	48
285	Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nature Genetics, 1997, 17, 226-230.	21.4	322
286	Molecular Monitoring of Minimal Residual Disease in Follicular and Mantle Cell Non-Hodgkin's Lymphomas Treated With High-Dose Chemotherapy and Peripheral Blood Progenitor Cell Autografting. Blood, 1997, 89, 724-491.	1.4	158
287	A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia, 1997, 11, 1793-1798.	7.2	99
288	Analysis of the immunoglobulin heavy-chain gene rearrangement providing molecular evidence of second lymphoma in a patient in apparent relapse after autotransplantation. Bone Marrow Transplantation, 1997, 20, 341-343.	2.4	7

#	Article	IF	CITATIONS
289	Peripheral blood progenitor cell mobilization in patients with primary refractory lymphoma or at first relapse: comparison with patients at diagnosis and impact on clinical outcome. British Journal of Haematology, 1997, 99, 41-46.	2.5	15
290	Multiple myeloma: reduced plasma cell contamination in peripheral blood progenitor cell collections performed after repeated high-dose chemotherapy courses. British Journal of Haematology, 1997, 99, 685-691.	2.5	16
291	Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood, 1996, 88, 2228-2235.	1.4	197
292	Clinical and molecular remission after allogeneic blood cell transplantation in a patient with mantle-cell lymphoma. British Journal of Haematology, 1996, 94, 376-378.	2.5	28
293	Oncogenes in the Pathogenesis of Multiple Myeloma. , 1996, , 169-172.		0
294	Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. Bone Marrow Transplantation, 1996, 18, 1117-21.	2.4	20
295	High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood, 1995, 85, 1596-1602.	1.4	133
296	Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma EMBO Journal, 1995, 14, 6209-6217.	7.8	243
297	Haematological support of high-dose sequential chemotherapy: Clinical evidence for reduction of toxicity and high response rates in poor risk lymphomas. Annals of Oncology, 1995, 6, S3-S8.	1.2	17
298	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood, 1994, 83, 1757-1759.	1.4	295
299	N- and K-Ras Oncogenes in Plasma Cell Dyscrasias. Leukemia and Lymphoma, 1994, 15, 17-20.	1.3	28
300	Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood, 1994, 83, 1757-1759.	1.4	76
301	Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia, 1994, 8, 758-67.	7.2	82
302	THE MUTATION OF N-RAS ONCOGENE DOES NOT INVOLVE MYELOID AND ERYTHROID LINEAGES IN A CASE OF MULTIPLE MYELOMA. British Journal of Haematology, 1993, 83, 672-673.	2.5	3
303	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-2713.	1.4	116
304	Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas Journal of Experimental Medicine, 1993, 178, 1091-1096.	8.5	109
305	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-2713.	1.4	2
306	Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood, 1993, 81, 2708-13.	1.4	31

#	Article	IF	CITATIONS
307	B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyt-10, homologous to NF-κB p50. Cell, 1991, 67, 1075-1087.	28.9	430
308	Dual rearrangement of immunoglobulin and Tâ€cell receptor gene in a case of Tâ€cell hairyâ€cell leukemia. European Journal of Haematology, 1991, 46, 71-76.	2.2	6
309	Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. Cancer Research, 1990, 50, 6478-82.	0.9	25
310	Philadelphia-positive thrombocythemia with a complex translocation involving chromosomes 9, 15, and 22. Cancer Genetics and Cytogenetics, 1989, 39, 77-80.	1.0	3
311	Free Calcium Concentration in Platelets of Patients with Essential Hypertension. American Journal of Nephrology, 1986, 6, 54-56.	3.1	3
312	New model of the origin of the stereospecificity in the synthesis of syndiotactic polypropylene. Macromolecules, 1985, 18, 2030-2034.	4.8	37
313	Analysis of models for the Ziegler-Natta stereospecific polymerization on the basis of non-bonded interactions at the catalytic site—I. The Cossee model. European Polymer Journal, 1979, 15, 1133-1141.	5.4	127
314	Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. Blood Advances, 0, , .	5.2	1